SynthesisWorld journal of surgical oncology2025
Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Radioembolization of primary liver tumors for patients with pre-existing ascites: beyond Child-Pugh score.Abdominal radiology (New York) · 2026Article
- Dexamethasone and N-acetylcysteine for the prevention of post-embolization syndrome following transarterial chemoembolization in hepatocellular carcinoma: a systematic review and network meta-analysis.Translational cancer research · 2026Article
- Analysis of risk factors and prediction of prognosis in patients with primary liver cancer undergoing transarterial chemoembolization.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the application effect of albumin-bilirubin (ALBI) classification in assessing the changes in liver function and prognosis of hepatocellular carcinoma (HCC) patients after transhepatic arterial chemoembolization (TACE).
methodsDatabases (such as Cochrane Library, PubMed, Embase, OVID, Web of Science) were used to collect and obtain all relevant studies on the changes in liver function and prognosis of HCC patients treated with TACE by ALBI classification. The literature was retrieved from the beginning of the database to September 2023. All analysis was performed by RevMan 5.4 software.
results20 papers with 10,223 patients were included. Meta-analysis showed that the overall survival (OS) after TACE was shorter in HCC patients with higher ALBI grades than in those with lower ALBI grades (2nd vs. 1st : OR = 1.52, 95% CI: 1.42-1.64, P < 0.00001; 3rd vs. 1st : OR = 2.67, 95% CI: 1.87-3.80, P < 0.00001; 3rd vs. 2nd : OR = 1.94, 95% CI: 1.67-2.26, P < 0.00001). ALBI worsened more with 2 TACE accumulations than with 1 TACE (OR = 1.78, 95% CI: 1.11-2.85, P = 0.02), more with 3 TACE accumulations than with 1 TACE (OR = 3.22, 95% CI: 1.96-5.29, P < 0.00001), and more with 3 TACE accumulations than with 2 TACE (OR = 1.70, 95% CI: 1.07-2.71, P = 0.03). In addition, ALBI predicted the occurrence of ACLF (OR = 4.57, 95% CI: 2.76-7.57, P < 0.00001).
conclusionALBI classification is clinically important in assessing the prognosis of TACE and predicting the risk of ACLF, and repeated TACE treatment may lead to increased liver function impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.